Aerovate Therapeutics, Inc.

General ticker "AVTE" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $136.5M (TTM average)

Aerovate Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -28.8%.

Estimated limits based on current volatility of 2.6%: low 2.63$, high 2.78$

Factors to consider:

  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.04$, 4.19$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.77$, 5.92$]

Financial Metrics affecting the AVTE estimates:

  • Negative: Non-GAAP EPS, $ of -2.44 <= 0.04
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -48.97 <= 1.79
  • Positive: Inventory ratio change, % of 0 <= 0
  • Positive: Shareholder equity ratio, % of 95.15 > 63.75
  • Negative: negative Operating income

Similar symbols

Short-term AVTE quotes

Long-term AVTE plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $53.24MM $81.41MM $74.60MM
Operating Income $-53.24MM $-81.41MM $-74.60MM
Non-Operating Income $1.75MM $5.94MM $5.02MM
R&D Expense $38.62MM $64.22MM $53.19MM
Income(Loss) $-51.49MM $-75.47MM $-69.57MM
Taxes $0.03MM $0.06MM $0.06MM
Profit(Loss)* $-51.51MM $-75.52MM $-69.63MM
Stockholders Equity $126.74MM $109.46MM $76.43MM
Assets $135.30MM $127.42MM $80.33MM
Operating Cash Flow $-39.12MM $-56.78MM $-71.20MM
Capital expenditure $0.20MM $0.14MM $0.00MM
Investing Cash Flow $6.93MM $11.88MM $56.03MM
Financing Cash Flow $0.40MM $46.00MM $25.43MM
Earnings Per Share** $-2.10 $-2.87 $-2.44

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.